About OCRA
About OCRA
OCRA is the world’s largest organization dedicated to fighting ovarian and all gynecologic cancers on all fronts while supporting patients and their families.
About OCRA
About OCRA
OCRA is the world’s largest organization dedicated to fighting ovarian and all gynecologic cancers on all fronts while supporting patients and their families.
Mission & Impact
Ovarian Cancer Research Alliance is the global leader in research funding and a trailblazer in the race to find a cure for ovarian and gynecologic cancers. Unafraid to challenge accepted wisdom, OCRA has taken powerful stances on everything from new recommendations for prevention to creating innovative, highly effective programs to promote education, advocacy, and awareness.
OCRA’s patient support programs, staffed by highly experienced social workers, are a model in the field. They offer dedicated assistance and empathetic support for those who need it most, no matter where they are in their cancer journey. Our goal is not only to improve treatments and attract the most gifted scientists to the field, but also to support patients and their families to ensure the best possible care and outcomes. We are passionately committed to inspiring hope, advancing science, and moving the world closer to a cure.
- Invested $140M in scientific breakthroughs
- $140M
- Helped secure $3.8B in federal research and education funding
- $3.8B
- Annually support more than 110K individuals through our programs
- 110K
Donate today
OCRA fulfills this mission by raising money — 81 cents of every dollar spent supports research and programs.
OCRA drives change and ignites hope
When it comes to curing ovarian cancer, only one organization has both a laser focus and a panoramic view.
Research
OCRA invests more funds into ovarian cancer research than any other public charity.
We are known for funding innovative projects, attracting young scientists and new energy to the field of ovarian cancer research. In addition, OCRA also supports mid-career scientists and senior researchers, investing in large grants for the latter to encourage collaboration among institutions.
Discover our research
Support and Knowledge
In times of adversity, OCRA offers hope and understanding.
OCRA’s compassionate Patient Support oncology social work team has decades of experience helping anyone touched by ovarian and any other gynecologic cancer. OCRA offers a comprehensive array of programs, including the following:
Find support
- Woman to Woman Peer Mentor Program – Available in more than 20 hospitals nationwide as well as virtually.
- Survivors Teaching Students® (STS) program – Ovarian cancer survivors and caregivers share their stories of diagnosis, treatment, and survivorship in medical education programs at more than 420 schools.
- Staying Connected Support Series – Led by our highly trained oncology social workers, our nationwide program of weekly and monthly online gatherings offer compassion, community, and support, including Express Yourself, sessions with therapeutic arts activities that ignite the joy of creativity, and Book Club, a monthly facilitated session that creates connection around a shared reading.
Advocacy
Advocacy is the lifeblood of change
OCRA has built a team of dedicated advocates who stand united in support of the cause. OCRA tirelessly urges Congress to prioritize the cause against ovarian cancer and related gynecologic cancers and is the only dedicated voice on Capitol Hill continuously advocating for hundreds of millions of dollars in federal research funding and for related health policies that benefit ovarian and all gynecologic cancer patients and survivors.
Take action now
Meet Our Team
OCRA’s effectiveness is due to the dedication and deep expertise of its outstanding staff, Board, and Scientific Advisory Committee members.
Our Partners & Sponsors
OCRA is fortunate to count many of the world’s leading companies and corporations as partners and sponsors. We thank them for supporting our mission to improve the lives of those affected by ovarian and other gynecologic cancers and to accelerate the search for a cure.
Conflict of Interest Statement — Industry Partners
- Corporate partners including industry do not shape OCRA’s agenda, research, or advocacy.
- In 2023, industry partners represented 8% of OCRA’s overall revenue.
- If an industry partner sponsors an OCRA program, grant, or educational materials, it is publicly acknowledged and the supporting company has no editorial or strategic input.
- Any reference to a specific commercial product or service does not constitute or imply an endorsement by OCRA of the product or service or its producer or provider. The views and opinions expressed in any referenced document or on any referenced website do not necessarily reflect those of OCRA.
News & Updates
New AI Accelerator Grant Captures Health and Science Media Attention
OCRA is excited to see the work fueled by our new AI Accelerator Grant resonating with a broad array of audiences. Since the Global Ovarian Cancer Research Consortium announced the inaugural AI Accelerator Grant on February 19, coverage has appeared across health, science, and business media outlets. The $1 million global research award—with an additional … Continued
The Overview: February 2026
The Global Ovarian Cancer Research Consortium and its inaugural AI Accelerator Grant have been making waves across health, science, and business media, reflecting widespread interest in what this work could mean for patients. The $1 million global research grant, plus an additional $1 million in compute support from Microsoft’s AI for Good Lab, will fund … Continued
Ovarian Cancer Research Alliance Honors Researchers with 2025 Rosalind Franklin and Schreiber Prizes
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued